Market capitalization | $50.44m |
Enterprise Value | $1.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.45 |
P/S ratio (TTM) P/S ratio | 12.77 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -74.60% |
Revenue (TTM) Revenue | $3.95m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
3 Analysts have issued a Aligos Therapeutics Inc forecast:
3 Analysts have issued a Aligos Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 3.95 3.95 |
75%
75%
|
|
Gross Profit | 1.32 1.32 |
89%
89%
|
|
EBITDA | -87 -87 |
2%
2%
|
EBIT (Operating Income) EBIT | -89 -89 |
1%
1%
|
Net Profit | -131 -131 |
50%
50%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Lawrence Blatt |
Employees | 70 |
Founded | 2018 |
Website | www.aligos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.